Player FMアプリでオフラインにしPlayer FMう!
Treating Myelodysplastic Syndrome by Downregulating the RAS Pathway with Dr. Steven Fruchtman Onconova Therapeutics
Manage episode 267708220 series 99915
Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.
@Onconova_ONTX
#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX
1725 つのエピソード
Manage episode 267708220 series 99915
Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.
@Onconova_ONTX
#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX
1725 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。